Neurociencia del consumo y dependencia de sustancias psicoactivas
Neurociencia del consumo y dependencia de sustancias psicoactivas Neurociencia del consumo y dependencia de sustancias psicoactivas
4. PSICOFARMACOLOGÍA DE LA DEPENDENCIA DE LAS DIFERENTES CLASES DE DROGASKalant H (1998) Research on tolerance: what can we learn from history?Alcoholism: Clinical and Experimental Research, 22:67–76.Kalant H (2001) The pharmacology and toxicology of “Ecstasy” (MDMA) andrelated drugs. Canadian Medical Association Journal, 165:917–928.Kalivas PW, Weber B (1988) Amphetamine injection into the ventral mesencephalonsensitizes rats to peripheral amphetamine and cocaine. Journal ofPharmacology and Experimental Therapeutics, 245:1095–1102.Kantak KM y colab. (2001) Time course of changes in cocaine self-administrationbehavior during immunization with the cocaine vaccine IPC-1010.Psychopharmacology, 153:334–340.Kenny PJ, Markou A (2001) Neurobiology of the nicotine withdrawal syndrome.Pharmacology, Biochemistry and Behavior, 70:531–549.Khanolkar AD, Palmer SL, Makriyannis A (2000) Molecular probes for thecannabinoid receptors. Chemistry and Physics of Lipids, 108:37–52.Kieffer BL (1999) Opioids: first lessons from knock-out mice. Trends inPharmacological Sciences, 20:537–544.Kieffer BL, Evans CJ (2002) Opioid tolerance: in search of the holy grail. Cell,108:587–590.Kita K y colab. (1999) Effects of D1 and D2 dopamine receptor antagonists oncocaine-induced self-stimulation and locomotor activity in rats. EuropeanNeuropsychopharmacology, 9:1–7.Knisely JS, Rees DC, Balster RL (1990) Discriminative stimulus properties oftoluene in the rat. Neurotoxicology and Teratology, 12:129–133.Koob GF (1992) Neural mechanisms of drug reinforcement. Annals of the NewYork Academy of Sciences, 28:171–191.Koob GF (1995) Animal models of drug addiction. Psychopharmacology: TheFourth Generation of Progress, 66:759–772.Koob GF and Bloom FE (1988) Cellular and molecular mechanisms of drugdependence. Science, 42:715–723.Koob GF and Nestler EJ (1997) The neurobiology of drug addiction. Journal ofNeuropsychiatry and Clinical Neuroscience, 9:482–497.Kornetsky C y colab. (1988) Brain stimulation reward: effects of ethanol.Alcoholism: Clinical and Experimental Research, 12:609–616.Kosten TR y colab. (2002) Human therapeutic cocaine vaccine: safety andimmunogenicity. Vaccine, 20:1196–1204.Krambeer LL y colab. (2001) Methadone therapy for opioid dependence.American Family Physician, 15:2404–2410.Kranzler HR (2000) Pharmacotherapy of alcoholism: gaps in knowledge andopportunities for research. Alcohol and Alcoholism, 35:537–547.Krausz M (2002): Modellprojekt: heroin als medicament [Modelo de proyecto:Heroína como medicación]. Deutsches Ärzteblatt, 99:A26–A28.Kreek MJ (2000) Methadone-related opioid agonist pharmacotherapy for heroinaddiction: history, recent molecular and neurochemical research and future in115
NEUROCIENCIA DEL CONSUMO Y DEPENDENCIA DE SUSTANCIAS PSICOACTIVASmainstream medicine. Annals of the New York Academy of Sciences, 909:186-216.Kuczenski R, Segal DS (1992) Differential effects of amphetamine anddopamine uptake blockers (cocaine, nomifensine) on caudate and accumbensdialysate dopamine and 3-methoxytyramine. Journal of Pharmacology andExperimental Therapeutics, 262:1085–1094.Kuhar MJ y colab. (2001) Anticocaine catalytic antibodies have no affinity forRTI compounds: implications for treatment. Synapse, 41:176–178.Lahti AC y colab. (1995) Ketamine activates psychosis and alters limbic bloodflow in schizophrenia. Neuroreport, 6:869–782.Leshner AI, Koob GF (1999) Drugs of abuse and the brain. Proceedings of theAssociation of American Physicians, 111:99–108.Ling W y colab. (1998) Buprenorphine maintenance treatment of opiatedependence: a multicenter, randomized clinical trial. Addiction, 93:475–486.Lodge D, Johnson KM (1990) Noncompetitive excitatory amino acid receptorantagonists. Trends in Pharmacological Sciences, 11:81–86.Luisada PV (1978) The phencyclidine psychosis: phenomenology and treatment.NIDA Research Monograph, 21:241–253.Lukas RJ y colab. (1999) Current status of the nomenclature for nicotinic acetylcholinereceptors and their subunits. Pharmacological Reviews, 51:397–401.McBride WJ (2002) Central nucleus of the amygdala and the effects of alcoholand alcohol-drinking behavior in rodents. Pharmacology, Biochemistry andBehavior, 71:509–515.McBride WJ, Li TK (1998) Animal models of alcoholism: neurobiology of highalcohol-drinking behavior in rodents. Critical Reviews in Neurobiology, 12:339–369.McCance-Katz EF, Kosten TR, Jatlow P (1998) Concurrent use of cocaine andalcohol is more potent and potentially more toxic than use of either alone: a multiple-dosestudy. Biological Psychiatry, 44:250–259.McCann U, Ricaurte G (1991) Lasting neuropsychiatric sequelae of methylenedioxymethamphetamine("Ecstasy") in recreational users. Journal of ClinicalPsychopharmacology, 11:302–305.Maccarrone M y colab. (1998) Anandamide hydrolysis by human cells in cultureand brain. Journal of Biological Chemistry, 273:32 332–32 339.McKenna DJ, Peroutka SJ (1990) Neurochemistry and neurotoxicity of 3,4-methylenedioxymethamphetamine, MDMA ("Ecstasy"). Journal ofNeurochemistry, 54:14–22.Maldonado R, Rodriguez de Fonseca F (2002) Cannabinoid addiction: behaviouralmodels and neural correlates. Journal of Neuroscience, 22:3326–3331.Malin DH (2001) Nicotine dependence studies with a laboratory model.Pharmacology, Biochemistry and Behavior, 70:551–559.Mansour A, Watson SJ (1993) Anatomical distribution of opioid receptors in mammalian:an overview. En: Hertz A, ed. Opioids I. Berlín, Springer-Verlag:79–105.Mansour A y colab. (1995) Opioid-receptor mRNA expression in the rat CNS:anatomical and functional implications. Trends in Neuroscience, 18:22–29.116
- Page 85 and 86: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 88 and 89: Capítulo 4Psicofarmacología de la
- Page 90 and 91: 4. PSICOFARMACOLOGÍA DE LA DEPENDE
- Page 92 and 93: 4. PSICOFARMACOLOGÍA DE LA DEPENDE
- Page 94 and 95: 4. PSICOFARMACOLOGÍA DE LA DEPENDE
- Page 96 and 97: 4. PSICOFARMACOLOGÍA DE LA DEPENDE
- Page 98 and 99: 4. PSICOFARMACOLOGÍA DE LA DEPENDE
- Page 100 and 101: 4. PSICOFARMACOLOGÍA DE LA DEPENDE
- Page 102 and 103: 4. PSICOFARMACOLOGÍA DE LA DEPENDE
- Page 104 and 105: 4. PSICOFARMACOLOGÍA DE LA DEPENDE
- Page 106 and 107: 4. PSICOFARMACOLOGÍA DE LA DEPENDE
- Page 108 and 109: 4. PSICOFARMACOLOGÍA DE LA DEPENDE
- Page 110 and 111: 4. PSICOFARMACOLOGÍA DE LA DEPENDE
- Page 112 and 113: 4. PSICOFARMACOLOGÍA DE LA DEPENDE
- Page 114 and 115: 4. PSICOFARMACOLOGÍA DE LA DEPENDE
- Page 116 and 117: 4. PSICOFARMACOLOGÍA DE LA DEPENDE
- Page 118 and 119: 4. PSICOFARMACOLOGÍA DE LA DEPENDE
- Page 120 and 121: 4. PSICOFARMACOLOGÍA DE LA DEPENDE
- Page 122 and 123: 4. PSICOFARMACOLOGÍA DE LA DEPENDE
- Page 124 and 125: 4. PSICOFARMACOLOGÍA DE LA DEPENDE
- Page 126 and 127: 4. PSICOFARMACOLOGÍA DE LA DEPENDE
- Page 128 and 129: 4. PSICOFARMACOLOGÍA DE LA DEPENDE
- Page 130 and 131: 4. PSICOFARMACOLOGÍA DE LA DEPENDE
- Page 132 and 133: 4. PSICOFARMACOLOGÍA DE LA DEPENDE
- Page 134 and 135: 4. PSICOFARMACOLOGÍA DE LA DEPENDE
- Page 138 and 139: 4. PSICOFARMACOLOGÍA DE LA DEPENDE
- Page 140 and 141: 4. PSICOFARMACOLOGÍA DE LA DEPENDE
- Page 142 and 143: 4. PSICOFARMACOLOGÍA DE LA DEPENDE
- Page 144 and 145: 4. PSICOFARMACOLOGÍA DE LA DEPENDE
- Page 146 and 147: Capítulo 5Bases Genéticas de lasF
- Page 148 and 149: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 150 and 151: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 152 and 153: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 154 and 155: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 156 and 157: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 158 and 159: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 160 and 161: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 162 and 163: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 164 and 165: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 166 and 167: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 168 and 169: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 170 and 171: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 172 and 173: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 174 and 175: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 176 and 177: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 178 and 179: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 180 and 181: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 182 and 183: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 184 and 185: 5. BASES GENÉTICAS DE LAS FARMACOD
NEUROCIENCIA DEL CONSUMO Y DEPENDENCIA DE SUSTANCIAS PSICOACTIVASmainstream medicine. Annals of the New York Aca<strong>de</strong>my of Sciences, 909:186-216.Kuczenski R, Segal DS (1992) Differential effects of amphetamine anddopamine uptake blockers (cocaine, nomifensine) on caudate and accumbensdialysate dopamine and 3-methoxytyramine. Journal of Pharmacology andExperimental Therapeutics, 262:1085–1094.Kuhar MJ y colab. (2001) Anticocaine catalytic antibodies have no affinity forRTI compounds: implications for treatment. Synapse, 41:176–178.Lahti AC y colab. (1995) Ketamine activates psychosis and alters limbic bloodflow in schizophrenia. Neuroreport, 6:869–782.Leshner AI, Koob GF (1999) Drugs of abuse and the brain. Proceedings of theAssociation of American Physicians, 111:99–108.Ling W y colab. (1998) Buprenorphine maintenance treatment of opiate<strong>de</strong>pen<strong>de</strong>nce: a multicenter, randomized clinical trial. Addiction, 93:475–486.Lodge D, Johnson KM (1990) Noncompetitive excitatory amino acid receptorantagonists. Trends in Pharmacological Sciences, 11:81–86.Luisada PV (1978) The phencyclidine psychosis: phenomenology and treatment.NIDA Research Monograph, 21:241–253.Lukas RJ y colab. (1999) Current status of the nomenclature for nicotinic acetylcholinereceptors and their subunits. Pharmacological Reviews, 51:397–401.McBri<strong>de</strong> WJ (2002) Central nucleus of the amygdala and the effects of alcoholand alcohol-drinking behavior in ro<strong>de</strong>nts. Pharmacology, Biochemistry andBehavior, 71:509–515.McBri<strong>de</strong> WJ, Li TK (1998) Animal mo<strong><strong>de</strong>l</strong>s of alcoholism: neurobiology of highalcohol-drinking behavior in ro<strong>de</strong>nts. Critical Reviews in Neurobiology, 12:339–369.McCance-Katz EF, Kosten TR, Jatlow P (1998) Concurrent use of cocaine andalcohol is more potent and potentially more toxic than use of either alone: a multiple-dosestudy. Biological Psychiatry, 44:250–259.McCann U, Ricaurte G (1991) Lasting neuropsychiatric sequelae of methylenedioxymethamphetamine("Ecstasy") in recreational users. Journal of ClinicalPsychopharmacology, 11:302–305.Maccarrone M y colab. (1998) Anandami<strong>de</strong> hydrolysis by human cells in cultureand brain. Journal of Biological Chemistry, 273:32 332–32 339.McKenna DJ, Peroutka SJ (1990) Neurochemistry and neurotoxicity of 3,4-methylenedioxymethamphetamine, MDMA ("Ecstasy"). Journal ofNeurochemistry, 54:14–22.Maldonado R, Rodriguez <strong>de</strong> Fonseca F (2002) Cannabinoid addiction: behaviouralmo<strong><strong>de</strong>l</strong>s and neural correlates. Journal of Neuroscience, 22:3326–3331.Malin DH (2001) Nicotine <strong>de</strong>pen<strong>de</strong>nce studies with a laboratory mo<strong><strong>de</strong>l</strong>.Pharmacology, Biochemistry and Behavior, 70:551–559.Mansour A, Watson SJ (1993) Anatomical distribution of opioid receptors in mammalian:an overview. En: Hertz A, ed. Opioids I. Berlín, Springer-Verlag:79–105.Mansour A y colab. (1995) Opioid-receptor mRNA expression in the rat CNS:anatomical and functional implications. Trends in Neuroscience, 18:22–29.116